Compare Marriott International Inc (MAR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Merck & Co., Inc. — how do they compare? Marriott International Inc trades at $360.95 (market cap $94.16B), while Merck & Co., Inc. trades at $141.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 3.7× Marriott International Inc 's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Merck & Co., Inc. for 98 Days on average.
| MAR | MRK | |
|---|---|---|
Market Cap | $94.16B | $351.28B |
Volume | 996,176 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $156.43 |
52-Week Low | $259.04 | $82.49 |
Typical Hold Time | 164 Days | 98 Days |
Enterprise Value | $111.47B | $398.04B |
Dividend Yield | 0.81% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.50, down 1.32% on the day, with a bullish technical signal from moving averages and support near $354. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%, though the P/E of 36.9 suggests a premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share payable in September 2026. Analyst consensus is a Buy with a $386.71 price target, indicating potential upside.
The outlook for MAR is positive, supported by strong travel demand and strategic partnerships, but risks include high debt levels and sensitivity to economic cycles. With institutional interest mixed and a neutral sentiment from oscillators, the stock offers growth potential tempered by valuation concerns and macroeconomic headwinds.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
